PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with Bevacizumab and Irinotecan

Technology in Cancer Research and Treatment

Volumn 5, Issue 1, 2006, Pages 37-43

  Goshen, Elinor ^a   Davidson, Tima ^a   Zwas, S Tzila ^a   Aderka, Dan ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti VEGF; Avastin; Bevacizumab; Liver; PET CT

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; INOPERABLE CANCER; LIVER BIOPSY; LIVER METASTASIS; MALE; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR NECROSIS;

EID: 33244485667     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460600500105     Document Type: Article

References (21)

1. Kabbinavar, F., Hurwitz, H., Fehrenbacher, L. et al. Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (Fu)/Leucovorin (Lv) with FU/LV Alone in Patients with Metastatic Colorectal Cancer. J. Clin. Oncol. 21, 60-65 (2003).
2. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. Bevacizumab Plus Irinotecan, 5-fluorouracil, and Leucovorin for the Treatment of Metastatic Colorectal Cancer: Results of a Randomized Phase III Trial. N. Engl. J. Med. 350, 2335-2342 (2004).
3. De Vore, R., Fehrenbacher, L., Herbst, R. et al. A Randomized Phase II Trial Comparing Rhumab VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor) Plus Carboplatin/Paclitaxel (CP) to CP Alone in Patients with Stage III/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 19, 485a (2000).
4. Yang, J. C., Haworth, L., Sherry, R. M. et al. A Randomized Trial of Bevacizumab, an Anti-vascular Endothelial Growth Factor Antibody, For Metastatic Renal Cancer. N. Engl. J. Med. 349, 427-434 (2003).
5. Bergsland, E., Dickler, M. N. Maximizing the Potential of Bevacizumab in Cancer Treatment. Oncologist. 9 Suppl 1, 36-42 (2004).
6. Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., Kabbinavar, F. Bevacizumab in Combination with Fluorouracil and Leucovorin: An Active Regimen for First-line Metastatic Colorectal Cancer. J. Clin. Oncol. 23, 3502-3508 (2005).
7. Harte, R. J., Mathews, J. C., O'Reilly, S. M. et al. Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation with N-phosphonacetyl-1-aspartate, Folinic Acid, and Interferon Alfa. J. Clin. Oncol. 17, 1580-1588 (1999).
8. Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., Mcconkey, D. J., Charnsangavej, C., O'Reilly, M. S., Kim, H. W., Baker, C., Roach, J., Ellis, L. M., Rashid, A., Pluda, J., Bucana, C., Madden, T. L., Tran, H. T., Abbruzzese, J. L. Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin. J. Clin. Oncol. 20, 3804-3814 (2002).
9. Carroll, V. A., Glaser, M., Aboagye, E. et al. Imaging Vascular Endothelial Growth Factor In Vivo with Positron Emission Tomography. Br. J. Cancer 83, 6 (2000).
10. Anderson, H., Yap, J., Price, P. M. Measurement of Tumour and Normal Tissue (NT) Perfusion by Positron Emission Tomography (PET) in the Evaluation of Antivascular Therapy: Results in the Phase I Study of Combrestatin A4 Phosphate (CA4P). Proc. Am. Soc. Clin. Oncol. 19, 179a (2000).
11. Rehman, S., Jayson, G. C. Molecular Imaging of Antiangiogenic Agents. Oncologist. 10, 92-103 (2005).
12. 18F]fluorodeoxyglucose and Positron Emission Tomography: A Pilot Study Following The Phase II Chemotherapy Schedule for Temozolomide in Recurrent High-grade Gliomas. Br. J. Cancer 82, 608-615 (2000).
13. Maisey, N. R., Webb, A., Flux, G. D. et al. FDG-PET in the Prediction of Survival of Patients with Cancer of the Pancreas: A Pilot Study. Br. J. Cancer 83, 287-293 (2000).
14. 18F]-fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations. European Organization For Research And Treatment Of Cancer (EORTC) Pet Study Group. Eur. J. Cancer 35, 1773-1782 (1999).
15. Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., Mino, M., Cohen, K. S., Scadden, D. T., Hartford, A. C., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., Chen, H. X., Shellito, P. C., Lauwers, G. Y., Jain, R. K. Direct Evidence that the VEGF-specific Antibody Bevacizumab has Antivascular Effects in Human Rectal Cancer. Nat. Med. 10, 145-147;
16. Erratum: Nat. Med. 10, 649 (2004).
17. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., Van Oosterom, A. T., Christian, M. C., Gwyther, S. G. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J. Natl. Cancer Inst. 2, 205-216 (2000).
18. Cobleigh, M. A., Langmuir, V. K., Sledge, G. W., Miller, K. D., Haney, L., Novotny, W. F., Reimann, J. D., Vassel, A. A Phase I/II Dose-escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer. Semin. Oncol. 30, 117-124 (2003)
19. 18F]-fluro-d-glucose Accumulation in Liver Tumours: Primary, Metastatic and after Chemotherapy. Nucl. Med. Commun. 13, 193-195 (1992).
20. 18F-FDG PET and PET/CT. Ajr. Am. J. Roentgenol. 184, 1096-102 (2005).
21. Jain, R. K. Normalizing Tumor Vasculature with Anti-angiogenic Therapy: A New Paradigm for Combination Therapy. Nat. Med. Sep 7, 987-989 (2001).